

Table of Contents

Content	Description	Page no.
	Abstract	i-ii
	Publications	iii
	Declaration	iv
	Certificates	v-vi
	Acknowledgement	vii-ix
	List of Abbreviations	x
	List of Figures	xi-xviii
	List of Tables	xiv
CHAPTER 1.1	Introduction	1-20
1.2	Development of human NK cells:	2-3
1.3	Human NK cell recognition of target cells: NK receptors	3-6
1.4	Natural killer cells in Cancer Biology:	6-7
1.5	NK cell mediated tumor immuno-surveillance:	8
1.6	NK Cell Anergy and Tumor Escape Mechanisms:	8-12
CHAPTER 2	Review of Literature	21-68
2.1	Introduction	21-23
2.1.1	Monocytes and Dendritic	23-24

	cells:	
2.1.2	Cytokines	25
2.1.3	T-cells:	25
2.1.4	Antigen Processing and Presentation:	26
2.1.4.1	Endogenous antigen presenting:	26
2.1.4.2	Exogenous antigen presenting :	26
2.1.5	NK cells	27
2.1.5.1	Identification of NK cells	27
2.1.5.2	Development of NK cells:	27
2.1.5.3	NK cell Inhibitory receptors:	28
2.1.5.4	NK cell Activating receptors	28
2.1.5.5	Regulation of NK cell receptors:	29
2.1.5.6	NK cell cytotoxicity	30
2.1.5.7	Memory NK cells:	30
2.2	Tumor immunology:	31
2.2.1	Immune surveillance:	31
2.2.2	Immune escape:	32
2.2.3	Tumor microenvironment:	32
2.2.3.1	Membrane bound proteins:	33
2.2.3.2	Tumor-induced transcriptions factors:	33
2.2.3.3	Secreted factors in the tumor microenvironment:	34
2.2.4	Immune suppression of NK cells:	34

2.2.4.1	Regulatory T cells:	34
2.2.4.2	Myeloid-derived suppressor cells:	35
2.2.4.3	Tumor-associated macrophages	35
2.2.4.4	Immune-regulatory Dendritic cells	35
2.2.5	Immunotherapy:	36
2.2.5.1	Targeting Treg	37
2.2.5.2	Targeting MDSC:	37
2.2.5.3	Immunological checkpoint Blocking	38
2.2.5.4	DC vaccines:	38
2.3.1	KIRs as targets:	39
2.3.2	Sensitization of tumor cells to NK cell-mediated killing:	40
2.3.3	Improve NK cell anti-tumor activity:	40
	CHAPTER 3	69-93
3.1	Introduction:	69-73
3.2	. Materials and methods	73
3.2.1.	Study site, study design, and participants	73
3.2.2	. Extraction of DNA, Quality assessment of the samples	74
3.2.3.	PCR based detection of KIR2DL1 Alleles	74
3.2.4	HLA-C Allotyping:	75
3.2.4	KIR2DL1 molecular modelling and Protein-	75-76

	Protein docking	
3.2.5	. Genetic analyses:	76
3.2.6	Statistical analysis	77
3.3	Results:	77
3.3.1	. Quality assessment of the DNA samples by β -globulin PCR	77
3.3.3	Genetic distances and Phylogenetic tree:	77-79
3.3.4	KIR2DL1 allotyping and KIR-HLA polymorphism:	79-81
3.3.5	KIR-HLA Nucleotide and Haplotype diversity:	81-84
3.3.6	Binding affinity study of KIR2DL1 alleles with HLA-C.	84-87
3.5	Discussion:	87-89
	CHAPTER-4	94-119
4.1	INTRODUCTION:	94-96
4.2.1	. Study site, study design, and participants	96-97
4.2.2	Variations in Copy Number of KIR2DL1/S1 and disease association	97-98
4.2.3	Gene expression assay:	98-101
4.2.4	Protein expression study by Immunohistochemistry:	101
4.2.5	. Statistical analysis of data	102
4.3.1	Patient characteristics:	102-103

4.3.2	Positive association of KIR2DL1*003-HLA-C2 genotype with HNSCC increases the odds of the disease at a younger age:	103
4.3.4	KIR2DL1*003 was the most frequent allele among the studied alleles:	104-105
4.3.5	Higher Copy Number of KIR2DL1 in KIR2DL1*003+HLA-C2+ genotype HNSCC patients:	106
4.3.6	SHP-2 expression and NK activation status:	110
4.3.7	: Cytokine expression in HNSCC regulates NK cell activation.	111
4.3.8	: High CNV of KIR2DL1 gene in patients with a history of cancer relapse:	111-112
4.4	Discussion:	112-115
	CHAPTER-5	120-135
5.1	INTRODUCTION:	120-123
5.2.1.	Study site, study design, and participants	123
5.2.2.	Preparation of cells from whole blood	124
5.2.3	Single-cell suspension culture of tumor tissue	125
5.3. 1.	Single-cell suspension culture	126-128
5.3.2	Tumor resident NK cells did not show decidual NK cell	128-130

	phenotype:	
5.4:	Discussion:	130-132
	CHAPTER-6	136-140
6.1	. Summary:	136
	Chapter-7	140-143
7.1	Future Prospects	143
	Appendix	144-147